Recent research have centered on the intersection of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic communication. While GIP stimulators are LL-37 increasingly employed for addressing type 2 diabetes, their unexpected effects on reinforcement circuits, specifically mediated by DA networks, are attracting substantial interest. This